23andMe Holding Co. (MEHCQ PINK) stock market data APIs
$4.3349
-0.24(-5.5%)
as of June 27, 2025
Try our APIs with
free plan!
23andMe Holding Co. Financial Data Overview
23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. It also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; offers non-controlled medications for treatment of acute and chronic conditions; and provides Ozempic and Wegovy through its weight loss program, offering consumers with access to affordable weight management care. In addition, the company provides research services. 23andMe Holding Co. was founded in 2006 and is headquartered in San Francisco, California.
Prev. Close
4.3349
Open
4.0951
High
4.4143
Low
4.0353
52 wk Range
0.47-10.8
Market Cap
0
EPS
-3.6206
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get 23andMe Holding Co. data using free add-ons & libraries
Get 23andMe Holding Co. Fundamental Data
23andMe Holding Co. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
23andMe Holding Co. News
New
The Score: 23andMe, U.S. Steel, Accenture and More Stocks That Defined the Week
23andMe said late Friday that TTAM Research Institute, Wojcicki’s nonprofit, was offering $305 million for the company’s assets. Last month, 23andMe said that biotech firm Regeneron had won the bi...
Regeneron is said to have declined a higher bid for 23andMe after Wojcicki's offer
[23andMe Headquarters] JasonDoiy/iStock Unreleased via Getty Images Regeneron Pharmaceuticals (NASDAQ:REGN [https://seekingalpha.com/symbol/REGN]) has reportedly declined to submit a higher bid for 2...
Anne Wojcicki's bid to buy back 23andMe may not end a legal fight over DNA customer data
Anne Wojcicki’s winning bid to reclaim control of 23andMe (MEHCQ) doesn’t necessarily end the fight over what happens to the DNA of 15 million people collected by the bankrupt consumer genomics co...
Anne Wojcicki's bid to buy back 23andMe may not end legal fight over DNA customer data
Anne Wojcicki's winning bid to reclaim control of 23andMe (MEHCQ) doesn't necessarily end the fight over what happens to the DNA of 15 million people collected by the bankrupt consumer genomics compan...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
